非小细胞肺癌中潜在可靶向TP53 Y220C突变的特征:欧洲胸部肿瘤平台多中心研究
该多中心回顾性研究纳入28244例有二代测序数据的NSCLC患者,发现195例(0.7%)携带TP53 Y220C突变,高于实体瘤平均0.4%。该突变在EGFR突变肿瘤中更常见(1.7% vs 0.7%,p=0.029),17.0%携带第二TP53突变,半数无已知驱动基因。结论建议NSCLC患者应筛查并纳入Y220C再激活剂临床试验。
要点
- NSCLC中TP53 Y220C突变率为0.7%,高于实体瘤平均0.4%。
- EGFR突变肿瘤中Y220C更常见(1.7% vs 0.7%,p=0.029)。
- 17.0%的Y220C患者携带第二TP53突变,可能与内在耐药相关。
核心结论
- TP53 Y220C在NSCLC中的频率与其他低丰度可靶向变异相似,应筛查患者并纳入Y220C再激活剂未来试验。
- TP53共突变应分析,因其可能与内在耐药相关。
研究设计与样本
- 多中心、欧洲胸部肿瘤平台赞助的回顾性研究,收集有二代测序数据的NSCLC患者资料。
- 共纳入28244例NSCLC患者。
主要发现
- 195例(0.7%)携带TP53 Y220C突变,高于实体瘤平均0.4%。
- 半数TP53 Y220C NSCLC患者不携带任何已知驱动基因。
- TP53 Y220C与性别、吸烟状态、组织学或分期无显著关联。
- EGFR突变肿瘤中Y220C患病率显著高于EGFR野生型(1.7% vs 0.7%;p=0.029)。
- 17.0%的Y220C患者携带第二TP53突变。
临床怎么用
- 对NSCLC患者进行TP53 Y220C筛查,并考虑纳入Y220C再激活剂临床试验。
- 分析TP53共突变,因其可能与内在耐药相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising results. The trial did not enrol any non-small cell lung cancer (NSCLC) cases, and little is known about the clinicopathological characteristics and genetic profile of the TP53 Y220C NSCLC patients. METHODS: In this multicenter, European Thoracic Oncology Platform-sponsored study, we retrospectively collected data from NSCLC patients from several European institutions with Next Generation Sequencing data available. RESULTS: The study included 28,244 NSCLC patients. We found that 195 (0.7%) harbored the TP53 Y220C mutation, a prevalence higher than the average in solid tumors (0.4%). Half of these TP53 Y220C NSCLC patients did not carry any known drivers. No significant association was observed between the TP53 Y220C and gender, smoking status, histology or stage. However, the mutation was significantly more prevalent in EGFR-mutant than EGFR-wild-type tumors (1.7% vs. 0.7%; p=0.029). Finally, 17.0% of Y220C patients carried a second mutation in TP53. CONCLUSIONS: The TP53 Y220C has a frequency similar to other low abundance, actionable alterations in NSCLC. Patients with NSCLC should be screened and included in future trials of Y220C reactivators. Co-mutations in TP53 should also be analyzed, since they might be associated with intrinsic resistance.
引用
- Molina-Vila MA, Tsourti Z, Stenzinger A, et al. Brief Report: Characterization of the Potentially Actionable TP53 Y220C Mutation in Non-Small Cell Lung Cancer. A Multicenter, European Thoracic Oncology Platform Study. J Thorac Oncol. 2026. PMID: 42901386. doi:10.1016/j.jtho.2026.106162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。